未破裂颅内动脉瘤术前抗血小板方案的疗效与安全性:单中心经验
该单中心回顾性研究分析了362例患者共400次手术(419个未破裂颅内动脉瘤)使用支架辅助弹簧圈或血流导向装置前的髙剂量抗血小板预用药方案,血栓栓塞并发症发生率5.75%,出血并发症4.75%,永久性手术相关病残率和死亡率分别为1.75%和1.25%。吸烟、高血压、血脂异常和年龄>65岁中多个心血管危险因素共存与永久性病残和血栓栓塞并发症显著相关,年龄单独与永久性病残及出血并发症相关。作者认为该髙剂量抗血小板预用药方案安全有效,出血并发症发生率较高且部分与死亡相关。
要点
- 血栓栓塞并发症发生率5.75%,多数为临床沉默性,永久性病残率1.75%,死亡率1.25%。
- 出血并发症发生率4.75%,比例较高且部分出血并发症与死亡相关。
- 吸烟、高血压、血脂异常和年龄>65岁中多个心血管危险因素共存与永久性病残(p=0.006)及血栓栓塞并发症(p=0.034)显著相关。
诊断标准与关键数值
- 血栓栓塞并发症发生于23/400次手术(5.75%),出血并发症发生于19/400次手术(4.75%)。
- 总体手术相关病残率为1.75%(n=7/400),死亡率为1.25%(n=5/400)。
- 吸烟、高血压、血脂异常和年龄>65岁中多个心血管危险因素共存与永久性手术相关病残显著相关(p=0.006),与血栓栓塞并发症发生显著相关(p=0.034)。
- 年龄单独与较高永久性病残相关(p=0.029),且是唯一与较高出血并发症相关的变量(p=0.024)。
临床应用与阅片要点
- 作者认为,髙剂量抗血小板预用药方案用于支架辅助弹簧圈或血流导向装置治疗未破裂颅内动脉瘤是安全有效的。
- 作者指出,血栓栓塞并发症发生率低且多数临床沉默,但出血并发症发生率较高且相当一部分与死亡相关。
- 作者报告,吸烟、高血压、血脂异常和年龄>65岁中多个心血管危险因素共存与永久性手术相关病残和血栓栓塞并发症发生显著相关,年龄单独与永久性病残及出血并发症相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: Endovascular treatment of unruptured intracranial aneurysms with stent-assisted coiling or flow diverter stents requires a prophylactic antiplatelet premedication to avoid thrombo-embolic complications. Guidelines for optimal antiplatelet regimens are poorly defined. The aim of this study is to report our experience using a high dosage antiplatelet premedication regimen for patients with unruptured intracranial aneurysms undergoing endovascular treatment by stent-assisted coiling or flow diverter stents.
METHODS: From a retrospective analysis of a prospectively maintained database, we collected clinical and angiographic data of 400 procedures in 362 patients treated by stent-assisted coiling or flow diverter stents for 419 unruptured intracranial aneurysms. Descriptive and analytic statistics were performed to report morbidity, mortality, and complication rates and to demonstrate associations between variables and outcomes. Logistic multivariable regression was performed to rule out confounding factors between subgroups.
RESULTS: Thrombo-embolic complications occurred in 23/400 procedures (5.75%) and hemorrhagic complications in 19/400 procedures (4.75%). The majority of complications were minor and transient with overall procedure-related morbidity and mortality rates of 1.75% (n = 7/400) and 1.25% (n = 5/400) respectively. The co-existence of multiple cardiovascular risk factors among smoking, hypertension, dyslipidemia, and age > 65 years old was significantly associated with permanent procedure-related morbidity (p = 0.006) and thrombo-embolic complications occurrence (p = 0.034). Age alone was associated with higher permanent morbidity (p = 0.029) and was the only variable associated with higher hemorrhagic complication (p = 0.024).
CONCLUSION: In this study, the use of a high dosage antiplatelet premedication was safe and effective for the treatment of unruptured intracranial aneurysms with stent-assisted coiling or flow diverter stents. Mortality and morbidity rates compare favorably with the current literature. The thrombo-embolic complications rate is low and most of them were clinically silent. However, the hemorrhagic complications rate was substantial and a significant proportion of them were associated with mortality.
引用
- Peret A, Mine B, Bonnet T, et al. Safety and efficacy of a pre-treatment antiplatelet regimen of unruptured intracranial aneurysms: a single-center experience. Neuroradiology. 2020. PMID: 32170373. doi:10.1007/s00234-020-02387-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。